Research progress of nano selenium in the treatment of oxidative stress injury during hepatic ischemia-reperfusion injury

Hepatic ischemia-reperfusion injury (HIRI) is an additional injury to ischemic tissue after hepatic revascularization, and its pathological mechanism is complex. HIRI is not only involved in the molecular targets that mediate cell death, such as ion channel activation, abnormal protease activation a...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in pharmacology Vol. 13; p. 1103483
Main Authors:	Deng, Xin, Ouyang, Peng, Xu, Wei, Yang, Erhua, Bao, Zhen, Wu, Yijing, Gong, Jin, Pan, Jinghua
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 04-01-2023
Subjects:	antioxidant HIRI nano selenium oxidative stress Pharmacology reactive oxygen species HIRI antioxidant nano selenium oxidative stress reactive oxygen species
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Hepatic ischemia-reperfusion injury (HIRI) is an additional injury to ischemic tissue after hepatic revascularization, and its pathological mechanism is complex. HIRI is not only involved in the molecular targets that mediate cell death, such as ion channel activation, abnormal protease activation and mitochondrial dysfunction, but also related to the down-regulation of endogenous protective signals. As a by-product of normal aerobic metabolism, reactive oxygen species (ROS) act as a multi effect physiological signal factor at low concentration. However, liver ischemia-reperfusion will lead to excessive ROS accumulation, destroy redox homeostasis, lead to oxidative stress, cause cell death through a variety of mechanisms, and drive the further damage of ischemic liver. Recent studies have found that the antioxidant treatment of nano selenium can reduce the excessive production of ROS and play a potential protective role in reducing HIRI. This paper reviews the molecular mechanism of the antioxidant effect of nano selenium for the prevention and treatment of HIRI, in order to provide further experimental basis for the clinical prevention and treatment of HIRI.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Qiu Xinguang, First Affiliated Hospital of Zhengzhou University, China Reviewed by: Luzhe Han, Southern Medical University, China Edited by: Jinhuan Jiang, University of South China, China This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology
ISSN:	1663-9812 1663-9812
DOI:	10.3389/fphar.2022.1103483